New ESC guidelines on hypertrophic cardiomyopathy: new insights in invasive treatment?

Hypertrophic cardiomyopathy (HCM) is a complex, yet relatively common genetic cardiac disease and has been the subject of intensive investigation since its first description in 1958. HCM is defined by the presence of an increased left ventricular wall thickness that is not solely explained by abnormal loading conditions. Histologically, HCM is characterised… CONTINUE READING